Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New combo therapy tested for advanced lung and colon cancers

NCT ID NCT05954871

First seen Nov 17, 2025 · Last updated May 24, 2026 · Updated 21 times

Summary

This early-phase study tested the safety of a new drug called GDC-1971 when given with either osimertinib (for lung cancer) or cetuximab (for colorectal cancer). It involved 10 adults with advanced cancer that had spread or couldn't be removed. The main goal was to check for side effects and find the right dose.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Asan Medical Center

    Seoul, 05505, South Korea

  • Border Medical Oncology

    Wodonga, New South Wales, 3690, Australia

  • SCRI Oncology Partners

    Nashville, Tennessee, 37203, United States

  • START South Texas Accelerated Research Therapeutics-San Antonio

    San Antonio, Texas, 78229, United States

  • Seoul National University Hospital

    Seoul, 03080, South Korea

  • St Vincent's Hospital Melbourne

    Fitzroy, Victoria, 3065, Australia

Conditions

Explore the condition pages connected to this study.